Posted by Michael Wonder on 15 Dec 2021
Wales is first UK country to fund GW’s Epidyolex for tuberous sclerosis
15 December 2021 - Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma’s cannabis based medicine Epidyolex, after the drug was cleared for use by the NHS.
Epidyolex (cannabidiol) can now be prescribed in Wales as a treatment for seizures associated with tuberous sclerosis complex, adding to its earlier approvals for Lennox-Gastaut syndrome and Dravet syndrome, two other forms of epilepsy.
